Lymphatica Medtech is developing a minimally invasive medical device that targets chronic lymphedema by facilitating lymphatic fluid drainage through a novel catheter-based system. This solution aims to reduce swelling and improve quality of life for patients suffering from this debilitating condition.
Funding
$19.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CVPPFounders
Product
Problem
Lymphedema, a chronic condition affecting over 10 million people in Europe and the USA, results in localized swelling due to the build-up of lymph under the skin, causing discomfort, pain, and recurring skin infections. Currently, there is no cure for lymphedema, and existing treatments often fail to effectively restore lymphatic drainage.
Solution
Lymphatica Medtech is developing LymphoDrain, an active implantable system designed to provide continuous lymph drainage in subcutaneous tissue for lymphedema patients. The system consists of a micro-pump/catheter implanted subcutaneously, a small wearable rechargeable controller, and a cloud-based software application. LymphoDrain aims to re-establish lymphatic circulation, reduce swelling, and improve the well-being of patients without impacting their lifestyle.
Target Audience
The primary target audience includes individuals suffering from chronic lymphedema and healthcare providers specializing in the treatment of lymphatic diseases.
Features
- Minimally invasive subcutaneous implantation of the micro-pump and catheter system
- Wearable, rechargeable controller for convenient operation
- Cloud-based software application for system management and monitoring
- Designed for continuous drainage of lymph fluid
- Aims to restore the natural lymphatic circulation